## COMMENTARY



## **Open Access**



# The whole truth and nothing but the truth: the need for full reporting of randomised trials

Rupert M. Pearse<sup>1,2</sup>

## Abstract


The use of cardiac output monitoring to guide fluid and inotropic therapy in surgical patients has remained a controversial topic for more than 40 years. The reasons for this are numerous and complex, but key amongst them is the interplay between poor research methodology and the likely selective reporting of randomised trials. In this issue of Perioperative Medicine, we find a very unusual report, one which describes a randomised trial stopped for futility after the recruitment of only a small proportion of the target patient sample (Jammer et al. Periop Med). The authors offer no statistical analysis of their findings but simply an explanation of what went wrong. On the face of it, this exercise would seem to offer little of value to the general reader. How can publication of the findings of an unsuccessful trial contribute to the evidence base on this topic? To understand this, we must delve a little deeper into the evidence and see how these trials were designed.

Keywords: Randomised trials, Fluid therapy, Methods, Monitoring, Physiologic, Surgery

### Background

Cardiac output-guided haemodynamic therapy is a complex intervention consisting of one or more therapeutic agents (fluid and/or inotropes), a monitoring device, and a human who interprets the data provided by this device using an algorithm, adjusting therapy doses accordingly. Trials of complex interventions have a particular set of limitations, so much so that in the UK, the Medical Research Council has developed methodological guidance on the design of such trials [1]. However, the sad truth is that many previous randomised trials of cardiac outputguided haemodynamic therapy have been of very poor methodological design. The key weaknesses are small patient samples recruited in single centres, use of subjective clinical outcome measures with no observer blinding to study group allocation, and the provision of control group care according to alternative algorithms which may be better or worse than usual clinical practice. These limitations are easily found, even amongst the most recent randomised trials, but if we search

Correspondence: r.pearse@qmul.ac.uk



#### Discussion

For this particular intervention, futility of the trial is likely to be associated with futility of the treatment. The investigators struggled to identify enough eligible patients for their trial and struggled to ensure they



© 2015 Pearse. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http:// creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

<sup>&</sup>lt;sup>1</sup>Barts & The London School of Medicine and Dentistry, Queen Mary University of London, London, UK

<sup>&</sup>lt;sup>2</sup>Adult Critical Care Unit, Royal London Hospital, London E1 1BB, UK

received the trial intervention. If we do not publish the results of unfinished trials, we will bias reporting towards 'positive' trials and create the false impression of an overall clinical benefit. Alternatively, if the outcome data from such trials are publically available, they may still be included in systematic reviews even if not subjected to statistical testing in the primary report. This counters the effect of publication bias. The second reason is less scientific but probably more important. Confidence in the evidence base has been systematically undermined by long running arguments between academics, many of whom have one vested interest or another in cardiac output guided therapy being shown to work. Counterintuitively, the publication of a report which does nothing to flatter those of us who work in this field does not undermine wider confidence in the evidence base but proves to the reader that a full and frank disclosure is taking place. All is in the public domain, nothing is hidden from sight, and all the relevant information can be taken into account as we formulate a view of the evidence. Jammer and colleagues must be congratulated for placing their work in the public domain, and the journal editors should be applauded for publishing it.

#### Conclusion

After 40 years and more than forty randomised trials, we remain uncertain about the perceived benefits of cardiac output-guided haemodynamic therapy. The findings of our own large multi-centre trial simply reinforce this uncertainty [2]. Only a very large multi-centre trial can provide the definitive answers we seek. Such a trial seems unlikely to happen, unless supported by both industry and major public funder(s). If this robust evidence cannot be provided, we should consider whether cardiac output monitoring adds value for our patients or is simply a distraction to the provision of high quality perioperative care.

#### **Competing interests**

In the last 5 years, RP has received equipment loans from LiDCO Ltd and has received honoraria for public speaking and/or consultancy work from Edwards Lifesciences and Massimo Inc. Previous to this, RP has received honoraria for public speaking and/or consultancy work from Covidien Inc and Pulsion Medical Systems.

#### Received: 17 April 2015 Accepted: 30 June 2015 Published online: 22 July 2015

#### References

- Campbell M, Fitzpatrick R, Haines A, Kinmonth AL, Sandercock P, Spiegelhalter D, et al. Framework for design and evaluation of complex interventions to improve health. BMJ. 2000;321(7262):694–6.
- Pearse RM, Harrison DA, MacDonald N, Gillies MA, Blunt M, Ackland G, et al. Effect of a perioperative, cardiac output-guided hemodynamic therapy algorithm on outcomes following major gastrointestinal surgery: a randomized clinical trial and systematic review. JAMA. 2014;311(21):2181–90.

## Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar

) BioMed Central

• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit